Sun’s De-Risked Gleevec Generic Set For 2016 US Launch
This article was originally published in PharmAsia News
Executive Summary
Shares of Sun Pharmaceutical spurted on Indian bourses after the firm's subsidiary received final US FDA approval for its ANDA for imatinib mesylate tablets 100mg and 400mg, generic versions of Novartis' chronic myeloid leukemia therapy Gleevec.